Curated News
By: NewsRamp Editorial Staff
October 13, 2026
Scinai Inks $5.1M Oncology Manufacturing Deal, Orders Soar 300%
TLDR
- Scinai Immunotherapeutics land a $5.1 million CDMO contract, boosting committed orders to $7.6 million, a 300% increase since year-end 2025.
- Scinai's subsidiary will provide development and clinical manufacturing for an oncology product, with revenue expected in 2026 and 2027, and stability services beyond.
- Scinai's expanded CDMO work supports development of oncology therapies, potentially improving patient outcomes and advancing medical science.
- Scinai's committed orders jumped from $1.9 million to $7.6 million, and an additional $5.85 million in uncommitted opportunities could extend through 2028.
Impact - Why it Matters
The substantial increase in committed orders signals growing demand for Scinai’s CDMO services and validates its strategic expansion. For investors, this revenue visibility—expected in 2026 and 2027—provides confidence in the company’s ability to scale and potentially achieve profitability. The potential additional $5.85 million in uncommitted opportunities further underscores the upside. In the competitive biopharma manufacturing landscape, such agreements are crucial for smaller players to establish credibility and secure long-term partnerships. Moreover, the deal involves an investigational oncology product, highlighting Scinai’s role in advancing cancer therapies, which could have broader implications for patients and the industry. As the CDMO market continues to grow, Scinai’s ability to attract and retain clients like this Nasdaq-listed biopharma demonstrates its operational excellence and positions it for sustained growth.
Summary
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company with a growing contract development and manufacturing organization (CDMO) and an immunology-focused therapeutic pipeline, has announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., has entered into a definitive development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company. The deal expands an existing customer relationship and includes approximately $5.1 million in committed base service fees, subject to performance and contractual terms. The engagement covers development and clinical manufacturing for an investigational oncology product, with revenue anticipated during 2026 and 2027 and stability services extending beyond 2027.
Following the agreement, Scinai’s committed customer orders across its Jerusalem and Yavne operations have reached approximately $7.6 million, a 300% increase from $1.9 million at year-end 2025 and more than double the $3.1 million reported in August 2026. The agreement also presents potential additional clinical manufacturing opportunities with an indicative, uncommitted value of $5.85 million for late 2027 through the first half of 2028, subject to further agreements and development milestones. To view the full press release, visit https://ibn.fm/5jaNp. Scinai Immunotherapeutics Ltd is focused on developing innovative immunology therapies, advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. The company also provides development and manufacturing services through its CDMO facilities in Israel. The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI. MissionIR is a specialized communications platform that assists IR firms with syndicated content to enhance visibility of private and public companies. It is part of the Dynamic Brand Portfolio @ IBN, which offers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Scinai Inks $5.1M Oncology Manufacturing Deal, Orders Soar 300%
